Influence of Hydration Status on the Yield of Injectable Platelet-Rich Fibrin

Influence of the Drinking Amount on the Autologous Blood in the Centrifuge Contained Fibrin Matrix - Platelet-rich Fibrin A Randomized Controlled Pilot Study

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07506252

Acronym

T-PRF

Enrollment

Registered

2026-04-01

Start date

2022-12-12

Completion date

2023-05-19

Last updated

2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behavior Change Interventions, Implant Dentistry, PRF

Keywords

PRF, Hydration, implant dentistry, regenerative dentistry

Brief summary

Due to the current lack of evidence regarding the influence of fluid intake on the amount of leukocyte- and platelet-rich fibrin fraction present in blood samples, this study aims to investigate the positive influence of this factor on the body's own matrix. Platelet-rich fibrin, a fibrin-rich autologous matrix obtained from autologous blood via centrifugation, contains not only fibrin but also important growth factors and a large number of white blood cells, all of which make a significant contribution to tissue regeneration. The obtained fibrin matrix can be used as a membrane, as a clot (A-PRF), or as a liquid (i-PRF) to positively influence the healing process. The novelty of this work lies in shifting the focus from purely technical centrifugation parameters to a patient-centered, easily modifiable biological variable. Hydration status represents a low-cost, non-invasive, and immediately applicable strategy to optimize autologous blood concentrates. These findings are directly relevant to clinicians seeking to enhance the predictability and efficiency of PRF-based regenerative procedures in implant dentistry.

Interventions

BEHAVIORALHydration following a drinking protocol

Participants followed a drinking protocol the day before the measurement to reach euhydration

Study design

Allocation

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

\- Healthy adults

Exclusion criteria

* coagulation disorders * anticoagulant medication * pregnancy * acute infections * systemic diseases with the potential to affect wound healing or blood composition

Design outcomes

Primary

Measure	Time frame	Description
PRF-Volume	3 visits, 3 weeks	Volume (ml) of i-PRF obtained from each 10 ml blood sample with low speed centrifugation

Secondary

Measure	Time frame	Description
PRF yield and height	3 visits, 3 weeks	Correlation of PRF yield in ml and height in cm
PRF yield and weight	3 visits, 3 weeks	Correlation of PRF yield in ml and weight in kg

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026